全文获取类型
收费全文 | 177569篇 |
免费 | 37479篇 |
国内免费 | 6664篇 |
专业分类
耳鼻咽喉 | 3208篇 |
儿科学 | 3453篇 |
妇产科学 | 3511篇 |
基础医学 | 13001篇 |
口腔科学 | 6525篇 |
临床医学 | 36564篇 |
内科学 | 36375篇 |
皮肤病学 | 4223篇 |
神经病学 | 16358篇 |
特种医学 | 6797篇 |
外国民族医学 | 54篇 |
外科学 | 26202篇 |
综合类 | 11320篇 |
现状与发展 | 62篇 |
一般理论 | 22篇 |
预防医学 | 18403篇 |
眼科学 | 5081篇 |
药学 | 9696篇 |
68篇 | |
中国医学 | 4361篇 |
肿瘤学 | 16428篇 |
出版年
2024年 | 747篇 |
2023年 | 6036篇 |
2022年 | 3837篇 |
2021年 | 6800篇 |
2020年 | 8263篇 |
2019年 | 4876篇 |
2018年 | 9849篇 |
2017年 | 9817篇 |
2016年 | 10489篇 |
2015年 | 11736篇 |
2014年 | 15078篇 |
2013年 | 16174篇 |
2012年 | 9916篇 |
2011年 | 10133篇 |
2010年 | 10858篇 |
2009年 | 12131篇 |
2008年 | 7740篇 |
2007年 | 6527篇 |
2006年 | 7774篇 |
2005年 | 6172篇 |
2004年 | 4210篇 |
2003年 | 3670篇 |
2002年 | 3124篇 |
2001年 | 3668篇 |
2000年 | 2973篇 |
1999年 | 3784篇 |
1998年 | 3361篇 |
1997年 | 3156篇 |
1996年 | 2907篇 |
1995年 | 2593篇 |
1994年 | 1862篇 |
1993年 | 1404篇 |
1992年 | 1375篇 |
1991年 | 1158篇 |
1990年 | 1008篇 |
1989年 | 966篇 |
1988年 | 904篇 |
1987年 | 713篇 |
1986年 | 640篇 |
1985年 | 544篇 |
1984年 | 405篇 |
1983年 | 406篇 |
1982年 | 282篇 |
1981年 | 265篇 |
1980年 | 161篇 |
1979年 | 154篇 |
1978年 | 165篇 |
1977年 | 142篇 |
1976年 | 107篇 |
1974年 | 115篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
11.
目的:通过调查、分析某二级公立医院员工满意度现状及影响因素,为探寻提升员工满意度路径提供依据。方法:按分层随机抽样法,抽取医院276名员工进行满意度问卷调查,对搜集到的数据进行统计分析。结果:医院员工满意度为(71.26±8.57)分;各维度评分中得分最高的是"领导与管理"维度,为(15.52±2.02)分;最低的是"薪酬与福利"维度,为(12.57±2.77)分。学历和岗位是影响该院员工满意度的主要因素。结论:医院员工满意度处于一般水平,医院应从健全薪酬福利机制、做好职业规划、重视不同群体需求、营造文化氛围等路径入手,提升员工满意度。 相似文献
12.
13.
14.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
15.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
16.
17.
卫逸涛肖惠敏谢银环孙丽军 《中华健康管理学杂志》2022,(8):547-552
目的了解老年人生命晚期获知疾病相关信息意向及影响因素。方法2016年10月至2017年6月,采用生命晚期疾病信息意向问卷,利用方便抽样法对福州市中心城区7所养老机构及15个社区的414例年龄≥60岁的老年人进行横断面调查,采用单因素分析、多元线性回归与有序多分类logistic回归分析老年人对疾病相关信息的需求水平、获知程度意向及其影响因素。结果414例老年人疾病相关信息需求得分为(17.1±4.9)分;48.8%(202/414)希望详尽知晓,30.7%(127/414)希望选择性了解,20.5%(85/414)不想知道任何信息;多元线性回归分析显示,年龄、文化程度、是否接受/见过其他生命维持治疗(LSTs)是影响老年人疾病相关信息需求水平的主要因素(标准化回归系数分别为-0.141、0.116、0.115,均P<0.05);有序多分类logistic分析显示,年龄(以60~69岁为参照,70~79岁:OR=0.544,95%CI:0.310~0.957;80~89岁:OR=0.526,95%CI:0.289~0.956)、文化程度(以小学及以下为参照,大专及以上:OR=2.166,95%CI:1.093~4.290)、主要生活费来源(以其他补贴为参照,家人支持:OR=7.303,95%CI:1.157~46.108;退休金:OR=9.288,95%CI:1.502~57.415;公积金/储蓄:OR=15.676,95%CI:2.122~115.793)、是否接受/见过其他LSTs(以是为参照,OR=1.985,95%CI:1.150~3.425)是影响老年人疾病相关信息获知程度意向的主要因素。结论老年人生命晚期获知疾病相关信息的意向程度较高,年龄、文化程度、主要生活费来源、是否接受/见过其他生命维持治疗等是其主要影响因素。 相似文献
18.
19.
20.
三阴性乳腺癌(triple negative breast cancer,TNBC)是雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人类表皮生长因子受体(human epidermal growth factor-2,HER-2)均不表达的乳腺癌。按其功能特征可归纳为5类分子分型:以DNA修复缺陷或生长因子为途径的基底细胞样三阴性乳腺癌;以上皮-间充质转化和肿瘤干细胞为特征的间质样三阴性乳腺癌;免疫调节型三阴性乳腺癌;雄激素受体过表达的管腔/分泌型三阴性乳腺癌;HER-2富集型三阴性乳腺癌。三阴性乳腺癌恶性程度高且异型性较大,其治疗困难且预后较差,内分泌治疗及靶向治疗不敏感。目前很多学者对于三阴性乳腺癌的治疗各有研究,并有临床试验证实下述治疗有效。 相似文献